Rezolute, Inc. (RZLT)
NASDAQ: RZLT · Real-Time Price · USD
9.49
0.00 (0.00%)
Oct 29, 2025, 3:46 PM EDT - Market open
Company Description
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States.
Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism.
The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017.
Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Rezolute, Inc.
| Country | United States |
| Founded | 2010 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 71 |
| CEO | Nevan Elam |
Contact Details
Address: 275 Shoreline Drive, Suite 500 Redwood City, California 94065 United States | |
| Phone | 650 206 4507 |
| Website | rezolutebio.com |
Stock Details
| Ticker Symbol | RZLT |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| CIK Code | 0001509261 |
| CUSIP Number | 76200L309 |
| ISIN Number | US76200L3096 |
| Employer ID | 27-3440894 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Nevan Elam | Chief Executive Officer |
| Daron Evans | Chief Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 21, 2025 | 8-K | Current Report |
| Oct 17, 2025 | SCHEDULE 13G | Filing |
| Oct 7, 2025 | DEF 14A | Other definitive proxy statements |
| Sep 22, 2025 | SCHEDULE 13G | Filing |
| Sep 17, 2025 | 10-K | Annual Report |
| Sep 17, 2025 | 8-K | Current Report |
| Sep 2, 2025 | 8-K | Current Report |
| Aug 20, 2025 | 8-K | Current Report |
| Aug 8, 2025 | EFFECT | Notice of Effectiveness |
| Aug 6, 2025 | SCHEDULE 13G/A | Filing |